Evidence map›Paper›PMID 23039107›Full record

ArticleNanoscale research letters2012

Hemopexin as biomarkers for analyzing the biological responses associated with exposure to silica nanoparticles.

Kazuma Higashisaka, Yasuo Yoshioka, Kohei Yamashita, Yuki Morishita, Huiyan Pan, Toshinobu Ogura, Takashi Nagano, Akiyoshi Kunieda, Kazuya Nagano, Yasuhiro Abe and 5 more

Open access · goldAbstract read
In one paragraph

Article in Nanoscale research letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 15 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Kazuma HigashisakaLaboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan. yasuo@phs.osaka-u.ac.jp.
Yasuo Yoshioka
Kohei Yamashita
Yuki Morishita
Huiyan Pan
Toshinobu Ogura
Takashi Nagano
Akiyoshi Kunieda
Kazuya Nagano
Yasuhiro Abe
Haruhiko Kamada
Shin-Ichi Tsunoda
Hiromi Nabeshi
Tomoaki Yoshikawa
Yasuo Tsutsumi
Osaka University · JPNational Institute of Biomedical Innovation, Health and Nutrition · JPNational Institute of Health Sciences · JPSanford Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Practical uses of nanomaterials are rapidly spreading to a wide variety of fields. However, potential harmful effects of nanomaterials are raising concerns about their safety. Therefore, it is important that a risk assessment system is developed so that the safety of nanomaterials can be evaluated or predicted. Here, we attempted to identify novel biomarkers of nanomaterial-induced health effects by a comprehensive screen of plasma proteins using two-dimensional differential in gel electrophoresis (2D-DIGE) analysis. Initially, we used 2D-DIGE to analyze changes in the level of plasma proteins in mice after intravenous injection via tail veins of 0.8 mg/mouse silica nanoparticles with diameters of 70 nm (nSP70) or saline as controls. By quantitative image analysis, protein spots representing >2.0-fold alteration in expression were found and identified by mass spectrometry. Among these proteins, we focused on hemopexin as a potential biomarker. The levels of hemopexin in the plasma increased as the silica particle size decreased. In addition, the production of hemopexin depended on the characteristics of the nanomaterials. These results suggested that hemopexin could be an additional biomarker for analyzing the biological responses associated with exposure to silica nanoparticles. We believe that this study will contribute to the development of biomarkers to ensure the safety of silica nanoparticles.

Identifiers

PMID23039107
PMCPMC3487985
OpenAlexW2115888330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.